Χώρα: Μάλτα
Γλώσσα: Αγγλικά
Πηγή: Medicines Authority
betahistine dihydrochloride 24 mg
Abbott Healthcare Products B.V.
N07CA01
betahistine dihydrochloride
tablet
Authorised
2008-02-07
UNWINDING NOT BETASERC 16/24MG RL 135X210 MT SAP CODE: 1060600 Pharma code : 692 NOTICE rouleau 135x210 RECTO Width: 135 mm Step: 210 mm Colour(s): BLACK Replaces: NA SOLVAY PHARMACEUTICALS CHATILLON EB 31-JAN-08 (edit. 1) Read this leaflet before you take your medicine as UNDESIRABLE EFFECTS it gives you some important information. If you In some cases mild gastric complaints have been have any questions or are not sure about anything, observed. These can normally be dealt with by ask your doctor or a pharmacist. taking the dose during meals or by lowering the dose. In very rare cases skin hypersensitivity reactions have been reported, in particular rash, pruritus and urticaria. OVERDOSE A few cases of overdose (up to 728 mg) with mild to BETAHISTINE DIHYDROCHLORIDE moderate symptoms have been reported . At a dose of 728 mg a convulsion was reported. In all cases recovery was complete. Treatment of overdose should include standard supportive measures. PHARMACODYNAMICS Carton with 60 scored tablets containing 16 mg The mechanism of action of betahistine is not betahistine dihydrochloride or 20 scored tablets known. Pharmacological testing in animals has containing 24 mg betahistine dihydrochloride. shown that the blood circulation in the inner ear improves, probably by means of a relaxation of the Tablets for oral administration. precapillary sphincters. In pharmacological studies, betahistine was found to have weak H 1 receptor Excipients: microcrystalline cellulose, mannitol, agonistic and considerable H 3 antagonistic properties citric acid mon Διαβάστε το πλήρες έγγραφο
Page 1 of 8 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Betaserc ® 8 mg tablets Betaserc ® 16 mg tablets Betaserc ® 24 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Betaserc ® tablets contain 8, 16 or 24 mg betahistine dihydrochloride. For a full list of excipients see section 6.1 3. PHARMACEUTICAL FORM Betaserc ® tablet, 8 mg: A round, flat, white to almost white tablet with bevelled edges. The diameter is 7 mm; the tablet weight is about 125 mg. The inscription is 256 on one tablet-side Betaserc ® tablet, 16 mg: A round, biconvex, scored, white to almost white tablet with bevelled edges. The diameter is 8.5 mm; the tablet weight is about 250 mg. The inscription is 267 on either side of the score on one tablet-side._ _ The tablet can be divided into equal halves Betaserc ® tablet, 24 mg: A round, biconvex, scored, white to almost white tablet with bevelled edges and relevant inscriptions. The diameter is 10 mm; the tablet weight is about 375 mg. The inscription is 289 on either side of the score on one tablet-side. _ _ The scoreline is only to facilitate breaking for ease of swallowing and not to divide into equal doses 4. CLINICAL PARTICULARS Page 2 of 8 4.1 THERAPEUTIC INDICATIONS Ménière's Syndrome as defined by the following trias of core symptoms: - vertigo (with nausea/vomiting) - hearing loss (hardness of hearing) - tinnitus Symptomatic treatment of vestibular vertigo. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Betaserc ® tablets 8mg/ Betaserc ® tablets 16mg: The dosage for adults is 24-48 mg divided over the day. _8 mg tablets _ _16 mg tablets _ 1-2 tablets 3 times Διαβάστε το πλήρες έγγραφο